Navigation Links
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Date:10/5/2007

h abnormal lipoprotein levels. Of these, more than 55 million are estimated to have low high density lipoprotein (HDL) and/or high triglyceride levels.

About Surface Logix, Inc.

Surface Logix, Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) with superior intrinsic drug- like properties that are clearly differentiated from competitive products. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.

Contact:

Leland Webster, Ph.D., M.B.A.

Surface Logix Inc.

Vice President, Corporate Development

617.746.8520

Media:

Sarah Cavanaugh

MacDougall Biomedical Communications, Inc.

scavanaugh@macbiocom.com

508.647.0209


'/>"/>
SOURCE Surface Logix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 1Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 2Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 3Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 1Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 2Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 3Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 4Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 5ScienceFirst Staff Expansion 58015 1
Other Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 2InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 3InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 4InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 5
Breaking Medicine News(10 mins):Health News:Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs 2Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 2Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 3Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 4Health News:New York Women's Agenda Presents AUA Foundation Executive Director Sandra Vassos with Star Award 2Health News:New York Women's Agenda Presents AUA Foundation Executive Director Sandra Vassos with Star Award 3Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 2Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 3Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 4Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 3